Amplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer.
FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).